在新冠疫情期间通过密切的流行病学监测支持儿科呼吸道合胞病毒临床试验。
Supporting Pediatric RSV Clinical Trials Through Close Epidemiological Surveillance During the SARS-CoV-2 Pandemic.
作者信息
Joshi Rennie, Nahhas Georges J, Arriola Carmen S, Saddier Patricia, Guerra Andrea
机构信息
Merck Sharp & Dohme LLC, Rahway, New Jersey, USA.
出版信息
Pharmacol Res Perspect. 2025 Jun;13(3):e70112. doi: 10.1002/prp2.70112.
Abstract
Clesrovimab, an extended half-life monoclonal antibody, aims to protect infants for an entire RSV season. The pandemic impacted RSV epidemiology and strategies were implemented to support clesrovimab trials. Near real-time monitoring of data showed minimal RSV activity in 2020. In 2021, RSV resurged early in some countries and was delayed in others, resulting in a change in trial enrollment strategy.
摘要
克来罗韦单抗是一种半衰期延长的单克隆抗体，旨在为婴儿提供整个呼吸道合胞病毒（RSV）流行季的保护。疫情影响了RSV的流行病学情况，并且实施了相关策略来支持克来罗韦单抗的试验。对数据的近实时监测显示，2020年RSV的活动极少。2021年，RSV在一些国家提前复发，而在其他国家则有所延迟，这导致了试验入组策略的改变。
相似文献
1
Supporting Pediatric RSV Clinical Trials Through Close Epidemiological Surveillance During the SARS-CoV-2 Pandemic.在新冠疫情期间通过密切的流行病学监测支持儿科呼吸道合胞病毒临床试验。
Pharmacol Res Perspect. 2025 Jun;13(3):e70112. doi: 10.1002/prp2.70112.
2
Comparison of clinical characteristics of hospitalized pediatric patients with respiratory syncytial virus infections before and during/after the coronavirus disease 2019 pandemic in Japan -importance of universal prevention using maternal vaccination and nirsevimab.日本2019冠状病毒病大流行之前以及期间/之后住院的呼吸道合胞病毒感染儿科患者临床特征的比较——母体疫苗接种和nirsevimab普遍预防的重要性
J Infect Chemother. 2025 Sep;31(9):102779. doi: 10.1016/j.jiac.2025.102779. Epub 2025 Aug 6.
3
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024.2023 - 2024年呼吸道合胞病毒疾病负担及尼塞韦单抗在幼儿中的有效性
JAMA Pediatr. 2025 Feb 1;179(2):179-187. doi: 10.1001/jamapediatrics.2024.5572.
4
Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants.呼吸道合胞病毒疾病负担及尼塞韦单抗预防和保护婴儿疾病效用的专家共识。
World J Pediatr. 2025 Jun 28. doi: 10.1007/s12519-025-00926-2.
5
Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital.评估尼塞韦单抗免疫接种对呼吸道合胞病毒细支气管炎住院率及其严重程度的影响：一项病例对照研究，并与一家三级儿科医院在新冠疫情前和后的季节进行比较。
Pediatr Pulmonol. 2025 Jul;60(7):e71059. doi: 10.1002/ppul.71059.
6
Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants.呼吸道合胞病毒单克隆抗体克来罗韦单抗的I期开放标签研究：中国健康受试者的安全性和耐受性
Hum Vaccin Immunother. 2025 Dec;21(1):2516948. doi: 10.1080/21645515.2025.2516948. Epub 2025 Jul 17.
7
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.帕利珠单抗预防高危婴儿和幼儿呼吸道合胞病毒（RSV）毛细支气管炎的免疫预防作用：亚组分析的系统评价和额外的经济建模。
Health Technol Assess. 2011 Jan;15(5):iii-iv, 1-124. doi: 10.3310/hta15050.
8
9
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial.Nirsevimab预防婴儿呼吸道合胞病毒下呼吸道感染住院治疗的180天疗效（HARMONIE）：一项随机对照3b期试验
Lancet Child Adolesc Health. 2025 Jun;9(6):404-412. doi: 10.1016/S2352-4642(25)00102-6.
10
A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.对帕利珠单抗用于呼吸道合胞病毒免疫预防给药依从性的系统评价。
J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. doi: 10.18553/jmcp.2010.16.1.46.
本文引用的文献
1
Seasonality of Respiratory Syncytial Virus - United States, 2017-2023.呼吸道合胞病毒的季节性 - 美国，2017-2023 年。
MMWR Morb Mortal Wkly Rep. 2023 Apr 7;72(14):355-361. doi: 10.15585/mmwr.mm7214a1.
2
International changes in respiratory syncytial virus (RSV) epidemiology during the COVID-19 pandemic: Association with school closures.在 COVID-19 大流行期间，呼吸道合胞病毒（RSV）流行病学的国际变化：与学校关闭的关联。
Influenza Other Respir Viruses. 2022 Sep;16(5):926-936. doi: 10.1111/irv.12998. Epub 2022 Jun 22.
3
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.2019 年全球、区域和国家因呼吸道合胞病毒导致 5 岁以下儿童急性下呼吸道感染的疾病负担估计：系统分析。
Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19.
4
Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic - United States, 2020-2021.COVID-19 大流行期间流感和其他呼吸道病毒活动的变化-美国，2020-2021 年。
MMWR Morb Mortal Wkly Rep. 2021 Jul 23;70(29):1013-1019. doi: 10.15585/mmwr.mm7029a1.
5
Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis.全球流感病毒、呼吸道合胞病毒、副流感病毒和偏肺病毒月度活动模式的系统分析。
Lancet Glob Health. 2019 Aug;7(8):e1031-e1045. doi: 10.1016/S2214-109X(19)30264-5.
6
Respiratory Syncytial Virus Seasonality - United States, 2014-2017.2014 - 2017年美国呼吸道合胞病毒季节性情况
MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):71-76. doi: 10.15585/mmwr.mm6702a4.
Zotero 插件